Neu­ro­crine ex­ecs shrug off a PhII set­back for Tourette syn­drome

Neu­ro­crine was forced to con­cede that its lead drug – al­ready on track at the FDA with an ap­pli­ca­tion for tar­dive dysk­i­ne­sia — just flunked a Phase II tri­al in Tourette syn­drome.

The VMAT2 in­hibitor im­proved symp­toms among the pa­tients tak­ing the drug, but failed to hit the pri­ma­ry end­point for the change-from-base­line in the Yale Glob­al Tic Sever­i­ty Scale at week 8. The biotech, though, is keep­ing the hard da­ta un­der wraps for now.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.